CD14 and myeloid sarcoma: In order to validate the nonquantitative proteomic analysis on all the 64 examined MS patients and 26 controls, using more quantitative assays, ELISA, we found increased levels of soluble CD14 protein (sCD14) in the CSF of MSlow compared to MShigh patients (P < 0.01).